Thu, August 6, 2009
Wed, August 5, 2009
Tue, August 4, 2009
Mon, August 3, 2009
Sat, August 1, 2009
Fri, July 31, 2009
Thu, July 30, 2009
Wed, July 29, 2009
Tue, July 28, 2009
Mon, July 27, 2009
Sat, July 25, 2009
Fri, July 24, 2009
Thu, July 23, 2009
Wed, July 22, 2009
Tue, July 21, 2009
Mon, July 20, 2009
Sun, July 19, 2009
Fri, July 17, 2009
Thu, July 16, 2009
Wed, July 15, 2009
Tue, July 14, 2009
Mon, July 13, 2009
Fri, July 10, 2009
Thu, July 9, 2009
Wed, July 8, 2009
Tue, July 7, 2009
Mon, July 6, 2009
Fri, July 3, 2009
Thu, July 2, 2009
Wed, July 1, 2009
Tue, June 30, 2009
Mon, June 29, 2009
Fri, June 26, 2009
Thu, June 25, 2009
Wed, June 24, 2009
Tue, June 23, 2009
Mon, June 22, 2009
Sun, June 21, 2009
Fri, June 19, 2009
Thu, June 18, 2009
Wed, June 17, 2009
Tue, June 16, 2009
Mon, June 15, 2009
Fri, June 12, 2009
Thu, June 11, 2009
Wed, June 10, 2009
Tue, June 9, 2009
Mon, June 8, 2009
Sun, June 7, 2009
Fri, June 5, 2009
Thu, June 4, 2009
Wed, June 3, 2009
Tue, June 2, 2009

Microbix Files First Patent Applications On Novel Technology Platform For Large Semen Sexing Market


//health-fitness.news-articles.net/content/2009/ .. logy-platform-for-large-semen-sexing-market.html
Published in Health and Fitness on Thursday, July 9th 2009 at 5:27 GMT, Last Modified on 2009-07-09 05:27:09 by Market Wire   Print publication without navigation


 Company seeks partner to commercialize the technology TORONTO, July 9 /CNW/ - Microbix Biosystems Inc. (TSX:MBX) announced today that it has filed key patent applications based on its novel semen sexing discoveries and that it will now embark on the path to commercialization of this exciting technology. Microbix' recent discoveries should provide a more cost-effective platform for semen sexing and significantly improve yields and quality of the sperm produced compared to the current commercial sexing technology. Both are critical market factors that Microbix believes will allow the company to effectively penetrate and even expand the $3 billion Artificial Insemination (AI) market. Semen sexing is instrumental to the dairy industry due to the growing international demand for female offspring and the negligible value of dairy bull calves. "This market is attractive for its size and the absence of regulatory barriers, and importantly, our technology offers a predictable pathway through development to market," said William J. Gastle, C.E.O. "Now that the intellectual property has been secured, we are focused on finding a strategic partner(s) to help realize Microbix' Semen Sexing Technology's (SST) significant commercial potential and we invite expressions of interest," said Mr. Gastle. Microbix specializes in the development of biological technologies and commercializing them through global partners. The Company has intellectual property in large market biotherapeutic drugs, vaccine technologies and animal reproduction technologies. Established in 1988, Microbix is headquartered in Mississauga. This press release contains forward-looking statements, which are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements including the risks associated with failure to develop and commercialize SST; non-adoption of SST. These forward-looking statements represent the Company's judgment as of the date of this press release. The Company disclaims any intent or obligation to update these forward-looking statements. %SEDAR: 00004220E 
For further information: visit [ www.microbix.com ] or contact: Phil Casselli, President, Microbix Biosystems Inc., (905) 361-8910 x 224; James Long, CFO, Microbix Biosystems Inc., (416) 234-1624 x 265 

Publication Contributing Sources

Similar Health and Fitness Publications